Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.63 |
| ▸ | HTR2A | P28223 | 6/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6952015 | 0.87 | SLC6A4 (0.62) | SLC6A4KCNH2HTR2AHRH3SLC6A3 | |
| SCHEMBL16453433 | 0.83 | LRRK2 (0.48) | SLC6A4KCNH2HTR2AHRH3SLC6A3 | |
| SCHEMBL6955582 | 0.83 | SLC6A4 (0.56) | SLC6A4KCNH2HTR2AHRH3SLC6A3 | |
| SCHEMBL6943332 | 0.83 | SLC6A4 (0.69) | SLC6A4KCNH2HTR2AHRH3SLC6A3 | |
| SCHEMBL6151915 | 0.83 | SLC6A4 (0.68) | SLC6A4KCNH2HTR2AHRH3SLC6A3 | |
| SCHEMBL6947444 | 0.81 | SLC6A4 (0.72) | SLC6A4KCNH2HTR2AHRH3SLC6A3 | |
| SCHEMBL7066916 | 0.79 | SLC6A4 (0.67) | SLC6A4KCNH2HTR2AHRH3SLC6A3 | |
| SCHEMBL8365509 | 0.79 | SLC6A4 (0.58) | SLC6A4KCNH2HTR2AHRH3SLC6A3 | |
| SCHEMBL15080265 | 0.78 | SLC6A4 (0.56) | SLC6A4KCNH2HTR2AHRH3SLC6A3 | |
| SCHEMBL3361902 | 0.78 | SLC6A4 (0.76) | SLC6A4KCNH2HTR2AHRH3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |